Beta-Adrenergic Antagonists

First-generation beta-blockers are non-selective, blocking both beta-1 and beta-2 receptors without preference. The prototype is propranolol. Non-selective blockade is clinically significant because beta-2 receptors mediate bronchodilation in airway smooth muscle and vasodilation in peripheral vasculature — blocking them causes bronchoconstriction and peripheral vasoconstriction in susceptible patients.

Second-generation agents are cardioselective, preferentially blocking beta-1 receptors while relatively sparing beta-2 receptors at standard doses. Prototypes include metoprolol, atenolol, and bisoprolol. This selectivity is relative and dose-dependent: at higher doses, beta-2 blockade becomes clinically significant even with cardioselective agents. The clinical advantage is reduced risk of bronchospasm and peripheral vasoconstriction compared with non-selective agents, though asthma remains an absolute contraindication for all beta-blockers regardless of selectivity.

Third-generation agents combine beta-blockade with additional vasodilatory mechanisms. Carvedilol adds alpha-1 blockade, providing direct arterial vasodilation on top of cardiac beta-blockade. Labetalol similarly combines alpha-1 and non-selective beta blockade. Nebivolol at higher doses generates nitric oxide-mediated vasodilation through endothelial pathways. The net result in all three is blood pressure reduction through both reduced cardiac output and reduced peripheral vascular resistance — a hemodynamic advantage in patients with HFrEF and coexisting hypertension.

Some beta-blockers are partial agonists at the beta receptor — they bind and partially activate the receptor while simultaneously blocking the effects of full agonists (epinephrine, norepinephrine). This property is called intrinsic sympathomimetic activity. Agents with intrinsic sympathomimetic activity (pindolol, acebutolol) produce less resting bradycardia because basal receptor activation is partially maintained. However, these agents have not demonstrated the mortality benefit in post-myocardial infarction or HFrEF populations that pure antagonists have, and they are not preferred for these indications.

Several beta-blockers (propranolol, acebutolol) have membrane-stabilizing activity — sodium channel blockade independent of beta-receptor antagonism, producing a quinidine-like effect that slows spontaneous depolarization. At therapeutic doses, this property is pharmacologically irrelevant because the concentrations needed for meaningful sodium channel blockade far exceed those producing beta-blockade. However, in massive overdose, membrane-stabilizing activity becomes clinically significant, contributing to wide-complex arrhythmias and profound cardiac depression in propranolol poisoning. Treatment of propranolol overdose includes intravenous sodium bicarbonate (to overcome sodium channel blockade, similar to tricyclic antidepressant overdose) and intravenous lipid emulsion.

Beta-blockers lower blood pressure by reducing heart rate and cardiac output, inhibiting renin release from juxtaglomerular cells (reducing angiotensin II and aldosterone), and — for lipophilic agents — suppressing central sympathetic outflow. Despite these mechanisms, beta-blockers are no longer recommended as first-line therapy for uncomplicated hypertension: meta-analyses have shown inferior reduction in stroke and mortality compared with diuretics, angiotensin-converting enzyme inhibitors, and calcium channel blockers.

They retain a strong first-line position when hypertension coexists with a compelling indication: post-myocardial infarction, HFrEF, angina, atrial fibrillation with rapid ventricular response, or hyperthyroidism. In these settings the beta-blocker addresses both the blood pressure and the underlying pathological process simultaneously.

In stable ischemic heart disease, beta-blockers reduce myocardial oxygen demand by slowing heart rate, reducing contractility, and lowering blood pressure. Slower heart rate also lengthens diastole, increasing coronary perfusion time and improving oxygen delivery to vulnerable subendocardial tissue. Beta-blockers are first-line therapy for chronic stable angina. In vasospastic (Prinzmetal) angina, non-selective agents are avoided because beta-2 blockade in coronary vessels leaves alpha-1-mediated vasoconstriction unopposed, potentially worsening coronary spasm. Calcium channel blockers are preferred in this setting.

Beta-blockers reduce mortality after myocardial infarction through suppression of the catecholamine surge that drives arrhythmias, reduction in infarct extension from decreased myocardial oxygen demand, and antifibrillatory effects from prolonged refractory periods. This is one of the most robustly established mortality benefits in cardiovascular medicine. Current guidelines recommend initiating oral beta-blocker therapy within the first 24 hours in hemodynamically stable patients without contraindications, and continuing for at least three years. Agents with demonstrated evidence include metoprolol, atenolol, carvedilol, and propranolol.

Beta-blockers improve survival in HFrEF despite being negative inotropes — an apparent paradox explained by the mechanism of harm in chronic heart failure. Sustained sympathetic overactivation in heart failure causes progressive beta-1 receptor downregulation, mitochondrial dysfunction, myocyte apoptosis, and maladaptive ventricular hypertrophy. Beta-blockade interrupts this cycle, allowing gradual receptor resensitization, reverse remodeling of the left ventricle, and improved ejection fraction over months of therapy.

Three specific agents have demonstrated mortality benefit in large randomized trials and are the only agents guideline-endorsed for HFrEF: carvedilol, bisoprolol, and extended-release metoprolol succinate. Other beta-blockers should not be substituted — the evidence base is agent-specific, not class-wide. These drugs must be initiated only when the patient is clinically stable and euvolemic — never during acute decompensation or cardiogenic shock. Starting doses are very low and doubled every two weeks as tolerated to target doses.

Beta-blockers exert class II antiarrhythmic effects by slowing sinoatrial node automaticity and prolonging atrioventricular node conduction and refractoriness. These actions make them the primary pharmacological tool for rate control in atrial fibrillation with rapid ventricular response, and for termination of atrioventricular nodal reentrant tachycardia. Propranolol is the preferred agent for arrhythmias caused by thyroid storm, pheochromocytoma (after alpha blockade is established), and catecholamine-triggered ventricular arrhythmias.

Negative chronotropy and negative dromotropy from beta-1 blockade are extensions of the therapeutic mechanism and represent the most common dose-limiting adverse effects. Symptomatic bradycardia at rest requires dose reduction or discontinuation. High-degree atrioventricular block (Mobitz type II or third-degree block) is an absolute contraindication to beta-blocker initiation, as further suppression of atrioventricular conduction can produce asystole. Sick sinus syndrome is similarly an absolute contraindication unless the patient has a functioning pacemaker. The risk of severe bradycardia is compounded by co-administration with other nodal-slowing agents — verapamil, diltiazem, digoxin, and amiodarone — combinations that require close monitoring.

Beta-2 blockade in airway smooth muscle reduces bronchodilatory tone and can precipitate life-threatening bronchospasm. Asthma is an absolute contraindication to all beta-blockers — including cardioselective agents, because even relative beta-1 selectivity does not provide complete protection in a highly reactive airway. Chronic obstructive pulmonary disease without significant reversible bronchospasm is a relative contraindication: low doses of cardioselective agents (bisoprolol, metoprolol) may be cautiously used when cardiovascular benefit clearly outweighs pulmonary risk, as in post-myocardial infarction or HFrEF. Topical ophthalmic beta-blockers can cause systemic bronchospasm via nasolacrimal absorption and require the same precautions.

Beta-blockers blunt the adrenergically mediated warning signs of hypoglycemia — tachycardia, palpitations, and tremor — in patients treated with insulin or insulin secretagogues. A critical clinical point: sweating is a cholinergically mediated response and is preserved, making it potentially the only remaining warning sign of hypoglycemia in a beta-blocked patient. Non-selective agents additionally impair glucagon-stimulated glycogenolysis and can prolong hypoglycemic episodes. Cardioselective agents are preferred in patients with insulin-dependent diabetes because beta-2-mediated glycogenolysis in the liver is relatively preserved.

Non-selective beta-blockers also increase triglycerides and reduce high-density lipoprotein cholesterol. Third-generation vasodilatory agents (carvedilol, nebivolol) have more metabolically neutral or favorable lipid profiles.

Chronic beta-blocker therapy causes upregulation of beta-adrenergic receptors in response to sustained blockade. Abrupt discontinuation exposes these upregulated, supersensitive receptors to normal circulating catecholamine levels, producing rebound tachycardia, hypertension, worsening angina, and — in patients with coronary artery disease — a real risk of myocardial infarction or sudden cardiac death. Beta-blockers must always be tapered gradually over one to two weeks whenever discontinuation is necessary. If urgent surgery or a procedure requires temporary cessation, the patient must be closely monitored for rebound cardiovascular events and the drug restarted as soon as feasible.

The most clinically hazardous pharmacodynamic interaction is the combination of beta-blockers with non-dihydropyridine calcium channel blockers — specifically verapamil and diltiazem, which slow sinoatrial and atrioventricular nodal conduction by independent mechanisms. Co-administration can produce severe bradycardia, high-degree atrioventricular block, or asystole. Intravenous verapamil should never be given to a patient receiving a beta-blocker. Additive nodal depression also occurs with digoxin and amiodarone.

Non-selective beta-blockers combined with epinephrine (as in anaphylaxis or local anesthetic use) produce the same unopposed alpha-1 vasoconstriction described in Module 2: beta-2-mediated vasodilation is blocked while alpha-1 vasoconstriction is unimpeded, causing paradoxical severe diastolic hypertension. Non-steroidal anti-inflammatory drugs blunt the antihypertensive efficacy of beta-blockers through prostaglandin-mediated sodium retention and vasoconstriction.